Business
Cerus Corporation Announces Symposium and Abstracts at the 33rd Regional ISBT Congress
Symposium and Abstracts Highlight Data from Studies of INTERCEPT Platelets and Plasma as well as Developmental Programs CONCORD, Calif.--(BUSINESS WIRE)--
About this update from Cerus Corporation
[{"type":"text","content":"\nSymposium and Abstracts Highlight Data from Studies of INTERCEPT Platelets and Plasma as well as Developmental Programs\n\n\n CONCORD, Calif.--(BUSINESS WIRE)--\nCerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and a lunch symposium at the 33rd Regional International Society of Blood Transfusion (ISBT) Congress, taking place in Gothenburg, Sweden, from June 17 through June 21. Transfusion medicine experts and professionals from around the world attend the ISBT Congress. This year marks the first time the conference has taken place in person since 2019.\n\n\nThe following is a select list of presentations and abstracts of interest for Cerus. All presentation times are listed in Central European Time (CET).\n\n\nOral Presentations\n\n\n\nMonday, June 19, 2023 – 12:30 p.m. – Cerus Lunch Symposium:\n\n\nImplementation of pathogen reduced products: considerations from the Canadian perspective and first experiences.\n\n\n\nImproving patient safety through pathogen inactivation: the Stanford experience.\n\n\n\nStrategies to reduce transfusion-transmitted bacterial infections: screening, pathogen inactivation, and cold stored platelets components.\n\n\n\n\n\n\nWednesday, June 21, 2023 – 9:15 a.m.– In Vitro Biochemical and Functional Comparison of Amotosalen-UVA-Treated Buffy-Coat Platelet Concentrates Stored in PAS-C Or PAS-E Additive Solution up to 7 Days\n\n\n\nPoster Presentations\n\n\nHeld between Sunday, June 18 and Tuesday, June 20, 2023\n\n\n\nPlatelet Safety Measures in Sweden: An Assessment of Current Practices and Comparison with International Practices\n\n\n\nIn Vitro Biochemical and Functional Characteristics of Stored (Double-Dose) Buffy-Coat Platelet Concentrates Treated With Amotosalen and a Prototype UVA Light-Emitting Diode Illuminator\n\n\n\nEvaluation of the In Vitro Properties Out to 7 Days of Buffy Coat Platelets Stored in PAS C Or PAS E and Treated With Amotosalen and a Prototype LED UVA Light Source\n\n\n\nInitial Experience of Switching Pathogen Inactivation System With Extended Platelet Shelf Life\n\n\n\nTransfusion of Amotosalen-UVA Pathogen Reduced Platelet Components to Mature and Premature Neonatal Infants\n\n\n\nAmotosalen/UVA Light Pathogen Reduced Plasma from Previously Quarantined Units Stored for Two Years\n\n\n\nA Pilot Study Tracking Pathogen Reduced RBCs In Vivo Using Surfac...